Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus standard-dose trastuzumab with chemotherapy for HER2-positive metastatic breast cancer
2007-006060-29Phase 3Terminated
- Sponsor
- Innovative Sensor Technology IST AG
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of trastuzumab in breast cancer (2 arms), sponsored by Innovative Sensor Technology IST AG. Primary endpoints: Time to progression and Progression-free survival. Started Nov 2007; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-006060-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006060-29.